International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumours

Trial Profile

International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumours

Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Zoledronic acid (Primary) ; Autologous stem cell therapy; Busulfan; Cyclophosphamide; Dactinomycin; Doxorubicin; Etoposide; Ifosfamide; Melphalan; Vincristine
  • Indications Ewing's sarcoma
  • Focus Therapeutic Use
  • Acronyms Euro Ewing 2012
  • Most Recent Events

    • 10 Dec 2015 Accrual to date is 17% according to United Kingdom Clinical Research Network record.
    • 04 Nov 2015 Accrual to date is 16% according to United Kingdom Clinical Research Network record.
    • 05 Oct 2015 Accrual to date is 13% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top